key: cord-0902225-0bn22sof
authors: Kreutzer, Adam G.; Krumberger, Maj; Diessner, Elizabeth M.; Parrocha, Chelsea Marie T.; Morris, Michael A.; Guaglianone, Gretchen; Butts, Carter T.; Nowick, James S.
title: A Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease
date: 2021-05-05
journal: Eur J Med Chem
DOI: 10.1016/j.ejmech.2021.113530
sha: 6b703b6652b9d1e016ba07075a02e533d71c0a3b
doc_id: 902225
cord_uid: 0bn22sof

This paper presents the design and study of a first-in-class cyclic peptide inhibitor against the SARS-CoV-2 main protease (M(pro)). The cyclic peptide inhibitor is designed to mimic the conformation of a substrate at a C-terminal autolytic cleavage site of M(pro). The cyclic peptide contains a [4-(2-aminoethyl)phenyl]-acetic acid (AEPA) linker that is designed to enforce a conformation that mimics a peptide substrate of M(pro). In vitro evaluation of the cyclic peptide inhibitor reveals that the inhibitor exhibits modest activity against M(pro) and does not appear to be cleaved by the enzyme. Conformational searching predicts that the cyclic peptide inhibitor is fairly rigid, adopting a favorable conformation for binding to the active site of M(pro). Computational docking to the SARS-CoV-2 M(pro) suggests that the cyclic peptide inhibitor can bind the active site of M(pro) in the predicted manner. Molecular dynamics simulations provide further insights into how the cyclic peptide inhibitor may bind the active site of M(pro). Although the activity of the cyclic peptide inhibitor is modest, its design and study lays the groundwork for the development of additional cyclic peptide inhibitors against M(pro) with improved activities.

Cyclic peptides are an important class of drugs. The binding affinities and specificities of cyclic peptides rival those of small molecule drugs and biomacromolecule drugs. 1, 2, 3, 4, 5, 6 Cyclic peptides often exhibit enhanced conformational stability and improved biological activity compared to linear analogues. 7, 8 This conformational rigidity increases resistance to degradation by endogenous proteases, leading to increased plasma stability. 9 Peptide cyclization can also facilitate passage of the peptide through a cell membrane. 10, 11 Although cyclic peptides often do not meet common physicochemical guidelines for drug-like cellular uptake and bioavailability, such as Lipinski's Rules of 5, a variety of cyclic peptide drugs are active against intracellular targets. 12, 13, 14, 15, 16, 17, 18 Secondary structure and backbone rigidity often impart a greater propensity for cyclic peptides to cross the plasma membrane. 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 The cyclic undecapeptide immunosuppressant drug cyclosporine A is an archetypal example for cell-permeable cyclic peptides. Despite its large size (MW = 1202 Da), cyclosporine A is orally bioavailable and passively crosses the plasma membrane. Cyclosporine A achieves its remarkable permeability and bioavailability by adopting a rigid secondary structure comprising two β-strands connected by a β-turn to form an antiparallel β-sheet. The amide backbone of cyclosporine A is also highly methylated, and the remaining unmethylated NH groups are intramolecularly hydrogen-bonded.

Cyclic peptide inhibitors that target viral proteins, such as the SARS-CoV-2 main protease (M pro ), may offer promise as antiviral drugs with pharmacological properties similar to cyclosporine A. M pro is one of the best-characterized drug targets for coronaviruses. 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 M pro cleaves the initially translated viral polyprotein into its component proteins within cells infected by SARS-CoV-2. Cleavage generally occurs immediately after a Gln residue, and the Gln residue is typically preceded by a hydrophobic J o u r n a l P r e -p r o o f residue, most often Leu. The residue that follows the Gln is often a small amino acid, such as Ser, Ala, or Asn. M pro autolytically cleaves itself from the polyprotein. 41 Inhibiting M pro activity slows or halts viral replication, offering the promise of improved clinical outcomes for COVID- 19 and other coronavirus diseases. Furthermore, there are no known human proteases with similar cleavage specificity to M pro , suggesting that it should be possible to develop inhibitors that target M pro without off-target toxicity.

Peptide-based inhibitors previously developed to target the SARS-CoV M pro have effectively been repurposed and modified to target the SARS-CoV-2 M pro -N3 from Jin et al.,

13b from Zhang et al., and 11a and 11b from Dai et al. 16, 42, 43 These inhibitors block SARS-CoV-2 replication in cell-based studies, making them promising antiviral drug candidates. While the M pro inhibitors N3, 13b, 11a, and 11b have shown promise against inhibiting SARS-CoV-2 replication, additional M pro inhibitors will most likely be needed for their improved properties or to be used in combination therapies. 44 In this paper, we describe the design and in vitro evaluation of UCI-1 (University of California, Irvine Coronavirus Inhibitor-1), a first-in-class cyclic peptide that we hypothesized would inhibit the SARS-CoV-2 M pro , which is required for viral replication ( Figure 1 ). UCI-1 is a cyclic pentapeptide containing four amino acids from a M pro substrate constrained in a macrocycle linked together with a [4-(2-aminoethyl)phenyl]-acetic acid (AEPA) group to create a paracyclophane. This rigidified macrocycle is designed to mimic the conformation of a Cterminal autolytic cleavage site of a naturally occurring M pro substrate. Evaluation of UCI-1 in an in vitro M pro inhibition assay reveals that UCI-1 inhibits the SARS-CoV-2 M pro at midmicromolar concentrations. LC/MS analysis indicates that UCI-1 resists cleavage by M pro , despite containing a scissile amide bond. Furthermore, UCI-1 is found to be non-toxic toward human embryonic kidney cells at concentrations that inhibit M pro . 45 J o u r n a l P r e -p r o o f 

Design of UCI-1. We designed the cyclic peptide inhibitor UCI-1 based on the crystal structure of an inactive SARS-CoV M pro (C145A) variant with a 10 amino-acid C-terminal extension corresponding to the C-terminal prosequence of M pro (PDB 5B6O) ("M pro 316 ", Figure   2 ). 46 The SARS-CoV M pro amino acid sequence is 96% identical to the SARS-CoV-2 M pro amino sequence, and the three-dimensional structure of the SARS-CoV-2 M pro is highly similar to the structure of the SARS-CoV M pro . 47 In the M pro 316 crystal structure, C-terminal residues 301-310 We recognized that upon linking Phe309 and Phe305 as described above, Phe305 and Gln306 were poised to form a β-turn in which the carbonyl group of AEPA hydrogen bonds with the amino group of Gly307. We envisioned that β-turn formation in the cyclic peptide inhibitor J o u r n a l P r e -p r o o f 8 would promote rigidity of the cyclic scaffold. To introduce additional conformational rigidity to the macrocycle, we also mutated Gly307 to serine, which is the most common residue at the P1' position among the 11 known SARS-CoV-2 M pro cleavage sites. The resulting cyclic peptide inhibitor UCI-1 was then further studied as described below. In an accompanying paper, we present a tutorial on the design process using free software. 48 Synthesis of UCI-1. We μM. Figure S1 shows the data from the continuous kinetic assay. Initial rates for M pro activity in the presence or absence of UCI-1 were obtained by fitting a straight line to the linear portions of the curves from the continuous kinetic assay. The % activity was calculated by comparing the initial rate at each concentration to the initial rate in the absence of inhibitor. Non-linear regression was then used to fit the data and estimate an IC 50 of ca. 160 μM for UCI-1 ( Figure   5A ).

Enzyme inhibition assay of UCI-1 (A) and control peptides peptide-1a (B) and peptide-1b (C). The activity of M pro was measured in the presence of increasing concentrations of UCI-1, peptide-1a, or peptide-1b. A dose-response curve was determined by non-linear regression and used to estimate the IC 50 . All data are shown as the mean of three technical replicates, with error bars representing the standard deviation. Panels D and E show the chemical structures of peptide-1a and peptide-1b.

To better understand the significance of inhibition of M pro by UCI-1, we synthesized and tested two control peptides derived from UCI-1the acyclic analog of UCI-1 "peptide-1a"

( Figure 5D ) and the diastereomer "peptide-1b" ( Figure 5E )that were predicted to not inhibit M pro . Peptide-1a exhibits little or no inhibition at concentrations at or below 750 μM ( Figure 5B ).

This finding indicates that the cyclic structure of UCI-1 is important for its activity. There is a slight reduction in rate of cleavage of the fluorogenic substrate upon addition of 1500 μM peptide-1a. This reduction in rate may reflect either slight inhibition of M pro or that the acyclic peptide acts as a competitive substrate at high concentrations. Peptide-1b exhibits little or no inhibition at concentrations at or below 1500 μM ( Figure 5C ). The inactivity of peptide-1b suggests that the shape and stereochemistry of UCI-1 are critical for fitting into and blocking the active site of M pro , and that inhibition by UCI-1 does not simply result from its hydrophobicity and cyclic structure. In the global minimum energy conformation, the AEPA residue acts as a rigid spacer, with Phe, Gln, Ser, and Lys forming a bridge. As we had envisioned, the Phe and Gln residues adopt a βturn conformation, with Phe at the i+1 position and Gln at the i+2 position. The Phe side chain is well situated to fit into the S2 pocket, and the Gln side chain is well situated to fit into the S1

pocket. The Ser, Lys, and AEPA residues, in turn, are poised to occupy the S1', S2', and S3' pockets.

J o u r n a l P r e -p r o o f peptide backbones of most of the conformers adopt the conformation described above, differing only in side chain geometry and the type of β-turn formed by Phe305 and Gln306 ( Figure 4B ).

To evaluate how UCI-1 might fit in the active site of M pro , we docked UCI-1 with the X-ray crystallographic structure of the SARS-CoV-2 M pro PDB 6YB7 using Autodock Vina. 50 This initial docking study revealed that UCI-1 fits into the active site of the SARS-CoV-2 M pro in the envisioned manner ( Figure 4C ).

J o u r n a l P r e -p r o o f complementary docking experiment on UCI-1, and then performed a molecular dynamics simulation on the docked structure. In this study, we first docked UCI-1 with an equilibrated version of the X-ray crystallographic structure of the SARS-CoV-2 M pro dimer PDB 6Y2E, which has previously been simulated in explicit water. 51 Next, we chose a low-energy configuration of UCI-1 bound to an equilibrated crystal structure of the M pro dimer PDB 6Y2E that best matched the docked structure observed in the initial docking experiment with PDB 6YB7. Finally, we performed 10 ns of molecular dynamics simulation of the docked structure using the CHARMM36 force field and TIP3P water at 310 Kelvin. This procedure was then repeated for peptide-1a and peptide-1b to gain insight into why these control peptides do not substantially inhibit M pro .

In the UCI-1 docking experiment, the side chains of UCI-1 occupy the active site M pro in the envisioned manner, where Phe occupies the S2 pocket, Gln occupies the S1 pocket, Ser occupies the S1' pocket, Lys occupies the S2' pocket, and the AEPA group occupies the S3' pocket ( Figure S2 ). Over the course of the simulation, UCI-1 stays bound to the active site and the amino acids maintain their positions in the pockets of the active site-only the Lys side chain appears to leave its respective pocket over the 10 ns simulation ( Figure S3 ). In contrast, the control peptides explore more of the active site and their side chains do not remain in their respective pockets as frequently. Notably, the D-Phe side chain of peptide-1b does not stay in the S2 pocket, and at times travels towards the S3' pocket, causing the peptide to lift away from the active site. The linear control, peptide-1a, does not appear to bind well in any of the pockets. Figure 7A ). 60 Nevertheless, we were able to synthesize cyclo(AEPA-FQ) and found that the cyclization proceeded smoothly, without the formation of detectable oligomers, uncyclized linear peptide, or side products. of the next generation of UCI-1 analogues will likely produce better inhibitors, and we anticipate that the studies described here will pave the way for the design of more potent cyclic peptide inhibitors of M pro with potential to be developed into drugs. We also anticipate that the AEPA unit will prove useful in the design of other conformationally constrained cyclic peptides with potential pharmacological applications. Figure 7C .

The initial SARS-CoV-2 M pro model that was used for MD simulations was generated from the final frame of the published wild type M pro trajectory, 50 which was originally seeded with PDB structure 6Y2E (see reference for details). Initial peptide conformations were obtained by docking UCI-1, peptide-1a, and peptide-1b respectively to the A chain active site of the initial M pro model using AutoDock Vina; 49 using VMD version 1.9.3; 68 a cubic water box with minimum margin of 10 Å from the protein complex on each side was employed, with NaCl added to achieve neutral charge. Each complex was subsequently minimized for 10,000 iterations using namd 2.13 69 with the CHARMM 36m force field, 70 followed by a 10 ps simulation period for box adjustment. (All simulations were performed using periodic boundary conditions with an NpT ensemble at 310K and 1 atm, Langevin dynamics with a damping coefficient of 1/ps and a Nosé-Hoover Langevin piston 71, 72 were respectively employed for temperature and pressure control. Rigid bonds were used only for water molecules, and a 1 fs step size was employed.) Following adjustment, each complex was simulated for 10 ns, with 1,000 frames being retained for subsequent analysis (1/ps).

Visualization and analysis of the resulting trajectories was performed with VMD.

J o u r n a l P r e -p r o o f

In vitro selection of highly modified cyclic peptides that act as tight binding inhibitors

Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges

Cyclic Peptides: Promising Scaffolds for Biopharmaceuticals. Genes (Basel)

Peptide-based Drug Discovery: Challenges and New Therapeutics

Constrained peptides' time to shine

Understanding Cell Penetration of Cyclic Peptides

Round and round we go: cyclic peptides in disease

Lessons from natural molecules

Enhancing the Cell Permeability and Metabolic Stability of Peptidyl Drugs by Reversible Bicyclization

Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers

Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides

Comprehensive analysis of loops at protein-protein interfaces for macrocycle design

The exploration of macrocycles for drug discovery--an underexploited structural class

Macrocycles in new drug discovery

Drug discovery: tools and rules for macrocycles

Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties

Form and function in cyclic peptide natural products: a pharmacokinetic perspective

The discovery and development of romidepsin for the treatment of T-cell lymphoma

Backbone rigidity and static presentation of guanidinium groups increases cellular uptake of arginine-rich cell-penetrating peptides

Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices

Helical Poly(arginine) Mimics with Superior Cell-Penetrating and Molecular Transporting Properties

Development of a Cell-penetrating Peptide that Exhibits Responsive Changes in its Secondary Structure in the

Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides

Perfluoroaryl Bicyclic Cell-Penetrating Peptides for Delivery of Antisense Oligonucleotides

Oxadiazole grafts in peptide macrocycles

Highly Conformationally Restricted Cyclopropane Tethers with Three-Dimensional Structural Diversity Drastically Enhance the Cell Permeability of Cyclic Peptides

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design

α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved αketoamide inhibitors

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements

Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases

Epub ahead of print

Bepridil is potent against SARS-CoV-2 in vitro

Proton-Coupled Conformational Activation of SARS Coronavirus Main Proteases and Opportunity for Designing Small-Molecule Broad-Spectrum Targeted Covalent Inhibitors

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Combination Prevention for COVID-19

An initial version of this work was deposited in bioRxiv on

SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved αketoamide inhibitors

Structure-Based Drug Design of an Inhibitor of the SARS-CoV-2 (COVID-19) Main Protease Using Free Software: A Tutorial for Students and Scientists

The fluorogenic M pro substrate we have synthesized and used in our studies contains a Dabcyl group on the ε-amine of lysine. Previous studies have used an isomer of this substrate with the Dabcyl group on the terminal amine

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Sequence Characterization and Molecular Modeling of Clinically Relevant Variants of the SARS-CoV-2 Main Protease

In vitro selection of highly modified cyclic peptides that act as tight binding inhibitors

Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges

Cyclic Peptides: Promising Scaffolds for Biopharmaceuticals. Genes (Basel)

Peptide-based Drug Discovery: Challenges and New Therapeutics

Constrained peptides' time to shine

Understanding Cell Penetration of Cyclic Peptides

An Unnatural Amino Acid that Mimics a Tripeptide β-Strand and Forms β-Sheet-like Hydrogen-Bonded Dimers

Functionalized analogues of an unnatural amino acid that mimics a tripeptide beta-strand

Cyclophane chemistry: bent and battered benzene rings

ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 -Preliminary Report

A new reagent for the cleavage of fully protected peptides synthesised on 2-chlorotrityl chloride resin

CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields

Extension of the CHARMM General Force Field to sulfonyl-containing compounds and its utility in biomolecular simulations

Automation of the CHARMM General Force Field (CGenFF) I: bond perception and atom typing

Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges

Comparison of simple potential functions for simulating liquid water

VMD: visual molecular dynamics

Scalable molecular dynamics with NAMD

CHARMM36m: an improved force field for folded and intrinsically disordered proteins

Constant pressure molecular dynamics algorithms

Constant pressure molecular dynamics simulation: The Langevin piston method